We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Surging Earnings Estimates Signal Good News for Crocs (CROX)
Read MoreHide Full Article
Crocs, Inc. (CROX - Free Report) is a renowned innovative casual footwear provider that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CROX’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Crocs could be a solid choice for investors.
Current Quarter Estimates for CROX
In the past 30 days, five estimates have gone higher for Crocs while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 53 cents a share 30 days ago to 68 cents today, a move of 28.3%.
Current Year Estimates for CROX
Meanwhile, Crocs’ current year figures are also looking quite promising, with five estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from $1.88 per share 30 days ago to $2.07 per share today, an increase of 10.1%.
The stock has also started to move higher lately, adding 17.9% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #1 (Strong Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Surging Earnings Estimates Signal Good News for Crocs (CROX)
Crocs, Inc. (CROX - Free Report) is a renowned innovative casual footwear provider that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CROX’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Crocs could be a solid choice for investors.
Current Quarter Estimates for CROX
In the past 30 days, five estimates have gone higher for Crocs while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 53 cents a share 30 days ago to 68 cents today, a move of 28.3%.
Current Year Estimates for CROX
Meanwhile, Crocs’ current year figures are also looking quite promising, with five estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from $1.88 per share 30 days ago to $2.07 per share today, an increase of 10.1%.
Crocs, Inc. Price and Consensus
Crocs, Inc. price-consensus-chart | Crocs, Inc. Quote
Bottom Line
The stock has also started to move higher lately, adding 17.9% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #1 (Strong Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>